-+ 0.00%
-+ 0.00%
-+ 0.00%

BioNTech Lowers FY26 Revenue Guidance

MT Newswires·08/04/2026 07:37:32
Listen to the news
07:37 AM EDT, 08/04/2026 (MT Newswires) -- BioNTech (22UA.F) revised its revenue guidance for full-year 2026, according to a Tuesday release. The Germany-based pharmaceutical group expects revenue of between 1.6 billion euros and 1.9 billion euros, down from its previous forecast of between 2 billion euros and 2.3 billion euros. BioNTech said it expects the majority of the 2026 revenue to be realized in the second half, specifically in the third quarter.